Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

746
(from Reference Citation Analysis)

Article PDFs (8)

Cited by ≥ 1 (102)

Searched Name

Yoshihiro Sakata

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Number	Citation Analysis
101	Sasaki T, Yuki S, Kawamoto Y, Harada K, Meguro T, Miyagishima T, Nakamura M, Sato A, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y. 190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00348-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
102	Ando T, Yuki S, Nakatsumi H, Muranaka T, Hosokawa A, Tsuji Y, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakata Y, Komatsu Y. 172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
103	Sasaki T, Yuki S, Kawamoto Y, Harada K, Meguro T, Miyagishima T, Nakamura M, Sato A, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y. 190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
104	Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Shinozaki K, Fukumoto K, Otsuji T, Kambara T, Morita S, Ando Y, Arai M, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
105	Fujihara M, Kin T, Yoshimura Y, Kajiwara Y, Ito M, Abe K, Sakata Y, Hiraki K, Ohtani S. Prognostic factors after neoadjuvant chemotherapy in breast cancer: Surgery type as a new prognostic factor. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
106	Taguchi Y, Hirai R, Sakata Y, Mori S. Template-Less Real-Time Robust Marker Tracking for Respiratory-Gated Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
107	Sakata Y, Hirai R, Taguchi Y, Mori S. Marker-less Tumor Tracking for Lung Cancer by Tumor Image Pattern Learning. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2259] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
108	Hirai R, Sakata Y, Taguchi Y, Mori S. Regression Model of Tumor and Diaphragm Position for Marker-Less Tumor Tracking in Carbon Ion Scanning Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
109	Yuki S, Komatsu Y, Muranaka T, Harada K, Sugiyama J, Tsuji Y, Ando T, Hosokawa A, Hatanaka K, Naruse H, Takahata T, Sato A, Kobayashi Y, Miyagishima T, Okuda H, Kudo M, Nakamura M, Hisai H, Sakamoto N, Sakata Y. Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
110	Sairyo M, Masuda D, Kobayashi T, Matsuda H, Okada T, Kawase R, Nakatani K, Koseki M, Ohama T, Nishida M, Sakata Y, Yamashita S. DPP4 inhibitor, anagliptin, ameliorates fasting and postprandial hypertriglyceridemia. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
111	Yuki S, Komatsu Y, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Tsuji Y, Hosokawa A, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakamoto N, Sakata Y. P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
112	Miyagishima T, Yuki S, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Kobayashi Y, Sasaki T, Nakamura M, Sato A, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y. P-152 Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
113	Nakamoto K, Ohtani T, Kioka H, Tsukamoto Y, Yoshioka D, Saito S, Toda K, Sawa Y, Sakata Y. Considering LV Dimension Is Important in Assessing the Risk of Right Ventricular Failure after Left Ventricular Assist Device Implantation. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.1104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
114	Hosokawa A, Yuki S, Kawamoto Y, Ando T, Muto O, Nakamura M, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Hayashi H, Fujikawa K, Kudo M, Honda T, Sakata Y, Komatsu Y. 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
115	Dazai M, Yuki S, Muranaka T, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Ohta T, Sato A, Eto K, Onodera K, Sato Y, Kato K, Nakamura M, Muto O, Ishiguro A, Tateyama M, Okuda H, Sakata Y, Komatsu Y. 158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
116	Komatsu Y, Yuki S, Nakatsumi H, Sawada K, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato K, Okuda H, Sogabe S, Miyagishima T, Miyashita K, Sakamoto N, Sakata Y. 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
117	Yuki S, Komatsu Y, Nakatsumi H, Muranaka T, Kobayashi Y, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Hisai H, Abe R, Sakamoto N, Oba K, Sakata Y. 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
118	Nakatsumi H, Yuki S, Kawamoto Y, Muranaka T, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato S, Okuda H, Sogabe S, Miyashita K, Sakata Y, Sakamoto N, Komatsu Y. 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31014-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
119	Kobayashi Y, Yuki S, Kawamoto Y, Sawada K, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Tagaki T, Hisai H, Koike M, Abe R, Sakata Y, Komatsu Y. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31016-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
120	Ichikawa W, Uehara K, Minamimura K, Tanaka C, Sadahiro S, Shinozaki K, Fukumoto K, Takii Y, Otsuji T, Kambara T, Gamoh M, Morita S, Ando Y, Arai M, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. 2100 Impact of UGT1A1 genotype and irinotecan exposure on outcomes in Japanese patients with advanced colorectal cancer treated by irinotecan-based regimens. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31022-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
121	Urushihara H, Noguchi Y, Sakata Y, Daidoji K, Sumitomo K, Ishii M, Geary S. 1015 Trends in the incidence of thyroid cancer and fine needle aspiration screening: Analysis of Japanese claims data. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30441-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
122	Nakamura M, Yuki S, Nakatsumi H, Muto O, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31018-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
123	Hatanaka K, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto O, Meguro T, Iwanaga I, Tsuji Y, Sato A, Eto K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Okuda H, Kudo M, Sakata Y, Komatsu Y. P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
124	Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost 2015;13 Suppl 1:S133-42. [PMID: 26149014 DOI: 10.1111/jth.12926] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Abstract Hemophilia is considered suitable for gene therapy because it is caused by a single gene abnormality, and therapeutic coagulation factor levels may vary across a broad range. Recent success of hemophilia B gene therapy with an adeno-associated virus (AAV) vector in a clinical trial showed the real prospect that, through gene therapy, a cure for hemophilia may become a reality. However, AAV-mediated gene therapy is not applicable to patients with hemophilia A at present, and neutralizing antibodies against AAV reduce the efficacy of AAV-mediated strategies. Because patients that benefit from AAV treatment (hemophilia B without neutralizing antibodies) are estimated to represent only 15% of total patients with hemophilia, the development of basic technologies for hemophilia A and those that result in higher therapeutic effects are critical. In this review, we present an outline of gene therapy methods for hemophilia, including the transition of technical developments thus far and our novel techniques. Collapse Key Words cell therapy gene therapy genetic hemophilia vectors viruses, adeno‐associated Collapse MESH Headings Animals Blood Coagulation/genetics Dependovirus/genetics Gene Transfer Techniques Genetic Predisposition to Disease Genetic Therapy/methods Genetic Vectors Hemophilia A/blood Hemophilia A/diagnosis Hemophilia A/genetics Hemophilia A/therapy Hemorrhage/blood Hemorrhage/diagnosis Hemorrhage/genetics Hemorrhage/therapy Humans Phenotype Collapse Grants Collapse
125	Yuki S, Komatsu Y, Muranaka T, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Kawamoto Y, Yoshizaki K, Sato A, Eto K, Onodera K, Kato S, Nakamura M, Muto O, Abe M, Sato Y, Ishiguro A, Tateyama M, Okuda H, Sakamoto N, Sakata Y. P-271 Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients: The HGCSG1401 Study -First Report-. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse